This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brock, N. Search for Related Content PubMed PubMed Citation Articles by Brock, N.

Oxazaphosphorine Cytostatics: Past-Present-Future

Seventh Cain Memorial Award Lecture¹

Department of Cancer Research, ASTA Pharma AG, D-4800 Bielefeld 14, Federal Republic of Germany

The development of the oxazaphosphorine cytostatics cyclophosphamide, ifosfamide, and trofosfamide was based on the idea of applying the transport form/active form principle to the highly reactive nitrogen mustard group. A critical analysis and synopsis of the available results and knowledge will include examination of the extent to which the hypotheses on which this concept is based have been confirmed by experimental and clinical findings:

1. Chemical synthesis succeeded in converting the reactive nitrogen mustard into an inactive transport form (latentiation).

2. The requirement that the transport form be enzymatically activated to the active form in the target organ (the cancer cell) has been achieved by a sequence of metabolic reactions.

3. The aim of considerably increasing the therapeutic index of alkylating agents has been achieved by the oxazaphosphorine cytostatics. The greater cancerotoxic selectivity is closely correlated with the cytotoxic specificity of their activated primary metabolites.

4. The cancerotoxic selectivity of oxazaphosphorines was further increased when mesna was introduced as a regional uroprotector. Mesna eliminates the risk of therapy-limiting urotoxic side effects of oxazaphosphorines. With mesna protection, these cytostatics can be given in higher doses with increased safety, and their therapeutic efficacy can be enhanced.

5. Stabilization of the primary oxazaphosphorines, e.g., by attaching 2-mercaptoethanesulfonic acid (mafosfamide), opens up new possibilities in preclinical investigations and in therapy, e.g., for the clonogenic stem cell assay, for in vitro purging in autologous bone marrow transplantation, for regional perfusion of tumors, and, in small doses, for immunomodulation, where appropriate, in conjunction with "biological response modifiers."

¹ Presented at the 79th Annual Meeting of the American Association for Cancer Research, May 25, 1988, New Orleans, LA.

Received 5/24/88. Revised 9/13/88. Accepted 9/29/88.

This article has been cited by other articles:

				K. Sasai, Y. Ikeda, T. Fujii, T. Tsuda, and N. Taniguchi UDP-GlcNAc concentration is an important factor in the biosynthesis of {beta}1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V Glycobiology, February 1, 2002; 12(2): 119 - 127. [Abstract] [Full Text] [PDF]

				E. Briasoulis, I. Judson, N. Pavlidis, P. Beale, J. Wanders, Y. Groot, G. Veerman, M. Schuessler, G. Niebch, K. Siamopoulos, et al. Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group J. Clin. Oncol., October 20, 2000; 18(20): 3535 - 3544. [Abstract] [Full Text] [PDF]

				E. Koscielniak, D. Harms, G. Henze, H. Jurgens, H. Gadner, M. Herbst, T. Klingebiel, B. F. Schmidt, M. Morgan, R. Knietig, et al. Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86 J. Clin. Oncol., December 1, 1999; 17(12): 3706 - 3719. [Abstract] [Full Text] [PDF]

				B. Bellosillo, N. Villamor, D. Colomer, G. Pons, E. Montserrat, and J. Gil In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia Blood, October 15, 1999; 94(8): 2836 - 2843. [Abstract] [Full Text] [PDF]

				C. Joqueviel, R. Martino, V. Gilard, M. Malet-Martino, P. Canal, and U. Niemeyer Urinary Excretion of Cyclophosphamide in Humans, Determined by Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy Drug Metab. Dispos., May 1, 1998; 26(5): 418 - 428. [Abstract] [Full Text]

				M. Veyhl, K. Wagner, C. Volk, V. Gorboulev, K. Baumgarten, W.-M. Weber, M. Schaper, B. Bertram, M. Wiessler, and H. Koepsell Transport of the new chemotherapeutic agent beta -D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1 PNAS, March 17, 1998; 95(6): 2914 - 2919. [Abstract] [Full Text] [PDF]